In this experiment, we used tumor-regressed mice because we could not enhance the negligible CT26-specific IFN-γ-producing CD8+ T cell responses seen in tumor-bearers in a DTA-1 dose-dependent manner. The gene discussed is IFNG; the disease is neoplasm.